Telix Pharmaceuticals (TLX) Competitors $9.54 -0.03 (-0.31%) Closing price 10/13/2025 04:00 PM EasternExtended Trading$9.56 +0.02 (+0.21%) As of 10/13/2025 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TLX vs. ASND, VTRS, RDY, MRNA, ROIV, QGEN, ELAN, BBIO, VRNA, and RVMDShould you be buying Telix Pharmaceuticals stock or one of its competitors? The main competitors of Telix Pharmaceuticals include Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Roivant Sciences (ROIV), QIAGEN (QGEN), Elanco Animal Health (ELAN), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. Telix Pharmaceuticals vs. Its Competitors Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories Moderna Roivant Sciences QIAGEN Elanco Animal Health BridgeBio Pharma Verona Pharma PLC American Depositary Share Revolution Medicines Ascendis Pharma A/S (NASDAQ:ASND) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk. Do analysts prefer ASND or TLX? Ascendis Pharma A/S currently has a consensus target price of $248.29, indicating a potential upside of 19.12%. Telix Pharmaceuticals has a consensus target price of $21.00, indicating a potential upside of 120.13%. Given Telix Pharmaceuticals' higher possible upside, analysts clearly believe Telix Pharmaceuticals is more favorable than Ascendis Pharma A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ascendis Pharma A/S 1 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 2.88Telix Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75 Does the media favor ASND or TLX? In the previous week, Ascendis Pharma A/S had 1 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 11 mentions for Ascendis Pharma A/S and 10 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 0.74 beat Ascendis Pharma A/S's score of 0.62 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Telix Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, ASND or TLX? Telix Pharmaceuticals has higher revenue and earnings than Ascendis Pharma A/S. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAscendis Pharma A/S$393.54M32.67-$409.12M-$5.16-40.39Telix Pharmaceuticals$516.72M6.25$32.93MN/AN/A Is ASND or TLX more profitable? Telix Pharmaceuticals has a net margin of 0.00% compared to Ascendis Pharma A/S's net margin of -54.94%. Company Net Margins Return on Equity Return on Assets Ascendis Pharma A/S-54.94% N/A -24.31% Telix Pharmaceuticals N/A N/A N/A SummaryTelix Pharmaceuticals beats Ascendis Pharma A/S on 7 of the 11 factors compared between the two stocks. Get Telix Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TLX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLX vs. The Competition Export to ExcelMetricTelix PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.24B$3.36B$6.05B$10.30BDividend YieldN/A2.31%5.73%4.82%P/E RatioN/A22.0885.3127.10Price / Sales6.25478.69601.46133.24Price / Cash83.8144.9825.7730.18Price / Book8.5210.3812.676.69Net Income$32.93M-$52.47M$3.32B$276.55M7 Day Performance-4.12%0.18%-0.06%-0.40%1 Month Performance3.58%13.95%8.73%6.53%1 Year PerformanceN/A20.83%78.85%41.04% Telix Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLXTelix Pharmaceuticals4.226 of 5 stars$9.54-0.3%$21.00+120.1%N/A$3.24B$516.72M0.00N/AASNDAscendis Pharma A/S3.1271 of 5 stars$210.83+3.3%$244.36+15.9%+61.7%$12.59B$393.54M-40.861,017Analyst ForecastHigh Trading VolumeVTRSViatris1.7203 of 5 stars$10.13-0.6%$10.40+2.7%-13.4%$11.88B$14.74B-3.4932,000RDYDr. Reddy's Laboratories2.4953 of 5 stars$14.12-0.3%$16.95+20.0%-8.3%$11.82B$3.81B21.3927,811MRNAModerna4.242 of 5 stars$27.54-3.3%$41.81+51.8%-54.1%$11.08B$3.24B-3.665,800ROIVRoivant Sciences3.3557 of 5 stars$16.26+0.6%$19.94+22.6%+36.2%$11.04B$29.05M-23.23860QGENQIAGEN4.3811 of 5 stars$46.99+0.4%$49.40+5.1%+10.8%$10.40B$1.98B27.765,765Analyst DowngradeELANElanco Animal Health2.5885 of 5 stars$20.68+0.2%$18.33-11.3%+39.5%$10.25B$4.44B24.059,000BBIOBridgeBio Pharma4.1442 of 5 stars$54.61+3.3%$63.94+17.1%+116.1%$10.11B$221.90M-13.35400VRNAVerona Pharma PLC American Depositary Share1.557 of 5 stars$106.91+0.1%$109.00+2.0%N/A$9.20B$42.28M-107.9930Positive NewsRVMDRevolution Medicines4.0792 of 5 stars$46.58-0.3%$74.64+60.2%-3.4%$8.73B$11.58M-10.35250 Related Companies and Tools Related Companies ASND Alternatives VTRS Alternatives RDY Alternatives MRNA Alternatives ROIV Alternatives QGEN Alternatives ELAN Alternatives BBIO Alternatives VRNA Alternatives RVMD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TLX) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredThe Army Just Got a New Drone SupplierA cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a...The Tomorrow Investor | SponsoredBlackRock’s Shocking Crypto MoveBlackRock, Fidelity, and JPMorgan have quietly shifted billions out of Bitcoin and into a single emerging cryp...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredU.S. Government Sparking Crypto RallyMissed Bitcoin when it was $100? You’re not alone. Crypto runs in cycles—and the next one is already underw...Crypto 101 Media | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telix Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Telix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
